PMDA — authorised 30 August 2022
- Marketing authorisation holder: AstraZeneca K.K.
- Status: approved
🇯🇵 CILGAVIMAB in Japan
PMDA authorised CILGAVIMAB on 30 August 2022
Marketing authorisation
CILGAVIMAB in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in Japan
Frequently asked questions
Is CILGAVIMAB approved in Japan?
Yes. PMDA authorised it on 30 August 2022.
Who is the marketing authorisation holder for CILGAVIMAB in Japan?
AstraZeneca K.K. holds the Japanese marketing authorisation.